Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06422949

Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy

Sponsor: European Institute of Oncology

View on ClinicalTrials.gov

Summary

Taxol is a very effective drug in breast cancer, but it can cause peripheral neuropathy (PN). This toxicity is often dose-limiting. Symptoms of PN usually improve after taxol discontinuation, but \>80% of affected women experience symptoms 1-3 years after treatment stop. The intensity, the duration and the type of symptoms related to PN are very different and they can strongly interfere with patients' quality of life. The application of cold to the hands and feet seems to be able to reduce the incidence of PN. Hilotherm® is a machine that allows to cool hands and feet. The aim of this study is to verify whether the use of Hilotherm® is able to reduce the incidence of moderate and severe PN and to evaluate the tolerability of Hilotherm® and its impact on quality of life.

Official title: A Study on the Efficacy and Safety of HILOTERM® Device for the Prevention of Chemotherapy-induced Peripheral Neuropathy in Early Breast Cancer Patients

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-06-15

Completion Date

2027-08-15

Last Updated

2024-05-31

Healthy Volunteers

Conditions

Breast Cancer Neuropathy;Peripheral

Interventions

DEVICE

Hilotherm® Cooling treatment

Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end

Inclusion Criteria: * Women \> 18 years of age * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 * Radically operated infiltrating breast cancer, pT1-T3, pN0-2, M0 * Candidate to adjuvant chemotherapy that includes weekly paclitaxel 80 mg/m2 intravenous for 12 weeks \[either following anthracyclines and/or in association with trastuzumab\] * Negative pregnancy test at baseline (in fertile women) * Willing and able to sign informed consent for protocol treatment Exclusion Criteria: * Evidence of metastatic disease (M1) * pT4 and/or pN3 * Previous or concomitant malignancy of any other type * Previous treatment with chemotherapy, hormonal therapy or an investigational drug for any type of malignancy * Plans to use a chemotherapy regimen other than those specified in the inclusion criteria * Any serious concurrent infection or any clinically significant medical illness (in particular clinically significant liver disease, clinically significant renal dysfunction, clinically significant cardiovascular disease, uncontrolled infections) which would jeopardize the ability of the patient to complete the planned therapy and follow-up * Pre-existing motor or sensory neuropathy of any grade, for any reason * Participation in any other clinical investigation or exposure to other investigational agents, drugs, device or procedure that may cause PN * History of Raynaud phenomenon, either primary or secondary to autoimmune or connective tissue diseases such as systemic lupus erythematous, scleroderma, Buerger disease, Sjögren syndrome, rheumatoid arthritis, occlusive vascular disease, such as atherosclerosis, polymyositis, cold agglutinin disease or cryoglobulinemia, thyroid disorders, pulmonary hypertension * Cold urticaria / cold contact urticaria * Severe arterial disease * Trophic tissue lesions * Diabetes mellitus * Alcohol abuse * History of severe allergic, anaphylactic, or other hypersensitivity reactions to the components of Hilotherm Chemo care device * Simultaneous use of Dignicap system to prevent hair loss from chemotherapy

Locations (1)

European Institute of Oncology

Milan, Italy